For a decade, women’s rugby was discussed almost entirely in terms of how quickly it could close the gap with the men’s game. Questions about attendance, broadcasting deals, and sponsorship dominated every
More
Spire Healthcare has undergone a significant boardroom overhaul following the completion of a £1.03bn takeover that will see the group delisted from the London Stock Exchange. Chief executive Justin Ash has announced
More
Reform UK leader Nigel Farage has admitted that an undercover investigation into his party’s approach to foreign donations “looks bad,” partially softening his earlier, more dismissive stance. Farage appeared on the BBC’s
More
In the fourth episode of the Talent Risk Assessor series, legal professionals examine how promotion timelines and tenure data connect to broader workforce retention concerns. The episode forms part of the Defensible
More
Manufacturers face greater exposure to tariff volatility than almost any other sector, according to legal experts at Foley and Lardner LLP. Changes in tariffs can increase input costs, disrupt production planning, undermine
More
Skadden and Kirkland have been hit with a combined $2 million fine after a judge determined the firms engaged in “a widespread, long-running cover-up.” The ruling marks a significant disciplinary moment for
More
U.S. District Judge Christopher Cooper has issued a preliminary injunction halting controversial changes to federal grant solicitations made by the Department of Health and Human Services. The ruling came in the case
More
A Stocks and Shares ISA remains one of the most effective wealth-building tools available to UK investors, with all returns sheltered from tax. That tax-free compounding effect can make a significant difference
More
ATI Inc. (ATI) has raised its financial outlook, signalling growing confidence in the company’s near-term revenue trajectory and operational momentum across its core markets. The upgraded guidance comes against a backdrop of
More
Oxford Biomedica, trading on the FTSE 250 under the ticker OXB, has caught the attention of market analysts who see significant room for growth in the coming year. The gene and cell
More